213 related articles for article (PubMed ID: 23845219)
1. Structure guided design of a series of sphingosine kinase (SphK) inhibitors.
Gustin DJ; Li Y; Brown ML; Min X; Schmitt MJ; Wanska M; Wang X; Connors R; Johnstone S; Cardozo M; Cheng AC; Jeffries S; Franks B; Li S; Shen S; Wong M; Wesche H; Xu G; Carlson TJ; Plant M; Morgenstern K; Rex K; Schmitt J; Coxon A; Walker N; Kayser F; Wang Z
Bioorg Med Chem Lett; 2013 Aug; 23(16):4608-16. PubMed ID: 23845219
[TBL] [Abstract][Full Text] [Related]
2. Rational design of SphK inhibitors using crystal structures aided by computer.
Ding T; Zhi Y; Xie W; Yao Q; Liu B
Eur J Med Chem; 2021 Mar; 213():113164. PubMed ID: 33454547
[TBL] [Abstract][Full Text] [Related]
3. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.
Plano D; Amin S; Sharma AK
J Med Chem; 2014 Jul; 57(13):5509-24. PubMed ID: 24471412
[TBL] [Abstract][Full Text] [Related]
4. Drugging sphingosine kinases.
Santos WL; Lynch KR
ACS Chem Biol; 2015 Jan; 10(1):225-33. PubMed ID: 25384187
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
Raje MR; Knott K; Kharel Y; Bissel P; Lynch KR; Santos WL
Bioorg Med Chem; 2012 Jan; 20(1):183-94. PubMed ID: 22137932
[TBL] [Abstract][Full Text] [Related]
6. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Magli E; Corvino A; Fiorino F; Frecentese F; Perissutti E; Saccone I; Santagada V; Caliendo G; Severino B
Curr Pharm Des; 2019; 25(9):956-968. PubMed ID: 30947653
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes.
Tao R; Zhang J; Vessey DA; Honbo N; Karliner JS
Cardiovasc Res; 2007 Apr; 74(1):56-63. PubMed ID: 17320845
[TBL] [Abstract][Full Text] [Related]
8. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.
Schröder M; Richter C; Juan MH; Maltusch K; Giegold O; Quintini G; Pfeilschifter JM; Huwiler A; Radeke HH
Mol Immunol; 2011 May; 48(9-10):1139-48. PubMed ID: 21435724
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases.
Kim JW; Kim YW; Inagaki Y; Hwang YA; Mitsutake S; Ryu YW; Lee WK; Ha HJ; Park CS; Igarashi Y
Bioorg Med Chem; 2005 May; 13(10):3475-85. PubMed ID: 15848761
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.
Patwardhan NN; Morris EA; Kharel Y; Raje MR; Gao M; Tomsig JL; Lynch KR; Santos WL
J Med Chem; 2015 Feb; 58(4):1879-1899. PubMed ID: 25643074
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine Kinase 2 Inhibition and Blood Sphingosine 1-Phosphate Levels.
Kharel Y; Morris EA; Congdon MD; Thorpe SB; Tomsig JL; Santos WL; Lynch KR
J Pharmacol Exp Ther; 2015 Oct; 355(1):23-31. PubMed ID: 26243740
[TBL] [Abstract][Full Text] [Related]
12. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors.
Mathews TP; Kennedy AJ; Kharel Y; Kennedy PC; Nicoara O; Sunkara M; Morris AJ; Wamhoff BR; Lynch KR; Macdonald TL
J Med Chem; 2010 Apr; 53(7):2766-78. PubMed ID: 20205392
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.
Kharel Y; Raje M; Gao M; Gellett AM; Tomsig JL; Lynch KR; Santos WL
Biochem J; 2012 Oct; 447(1):149-57. PubMed ID: 22747486
[TBL] [Abstract][Full Text] [Related]
14. Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.
Childress ES; Kharel Y; Brown AM; Bevan DR; Lynch KR; Santos WL
J Med Chem; 2017 May; 60(9):3933-3957. PubMed ID: 28406646
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase inhibitors: A patent review.
Cao M; Ji C; Zhou Y; Huang W; Ni W; Tong X; Wei JF
Int J Mol Med; 2018 May; 41(5):2450-2460. PubMed ID: 29484372
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.
Congdon MD; Childress ES; Patwardhan NN; Gumkowski J; Morris EA; Kharel Y; Lynch KR; Santos WL
Bioorg Med Chem Lett; 2015 Nov; 25(21):4956-4960. PubMed ID: 25862200
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase inhibitors: a review of patent literature (2006-2015).
Lynch KR; Thorpe SB; Santos WL
Expert Opin Ther Pat; 2016 Dec; 26(12):1409-1416. PubMed ID: 27539678
[TBL] [Abstract][Full Text] [Related]
18. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-β1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis.
Yang L; Chang N; Liu X; Han Z; Zhu T; Li C; Yang L; Li L
Am J Pathol; 2012 Jul; 181(1):85-97. PubMed ID: 22609227
[TBL] [Abstract][Full Text] [Related]
20. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways.
Pfaff M; Powaga N; Akinci S; Schütz W; Banno Y; Wiegand S; Kummer W; Wess J; Haberberger RV
Respir Res; 2005 May; 6(1):48. PubMed ID: 15927078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
